97160 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons; Interleukins [IL] IL-1
Methods of Treating Kawasaki Disease Using IL-1beta Antibodies
#2True human antibody specific for interleukin 1 alpha
#3True human antibody specific for interleukin 1 alpha
#4True human antibody specific for interleukin 1 alpha
#5Methods of Using IL-1beta Compounds
#6Liquid Pharmaceutical Formulations for an Anti-IL-1beta Antibody
#7LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE, PREPARATION METHOD THEREFOR, AND USES THEREOF
#8ANTI-IL-1ß ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF AND USE OF SAME
#9SINGLE-CHAIN CANAKINUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS
#10Methods of Treating Hidradenitis Suppurativa with Anti-IL-1beta Antibodies
#11HOMOGENEOUS ANTIBODY POPULATIONS
#12INHIBITOR OF INTERLEUKIN-1 RECEPTOR TYPE 1 FOR USE IN THE TREATMENT OF CANCER
#13SENOTHERAPEUTIC AGENTS AND ALPHA-KLOTHO POLYPEPTIDES
#14MONOCLONAL ANTI-IL-1RACP ANTIBODIES
#15PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES, CONTAINING GLUCAGON-LIKE PEPTIDE-1 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST
#16Arthritis Treatment
#17ANTI-IL-1-BETA ANTIBODIES
#18Gout flare prevention methods using IL-1BETA blockers
#19COMBINATIONS OF ANTI-INFLAMMATORY AGENTS FOR TREATING ACUTE ORGAN FAILURE, ARDS, ORGANS FOR TRANSPLANTATION OR DISEASES CAUSED BY AN AIRWAY-TARGETING VIRUS
#20METHOD OF MANUFACTURING BISPECIFIC ANTIBODIES, BISPECIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES
#21Epitope Modification
#22BISPECIFIC ANTIBODIES FOR USE IN TREATMENT OF HIDRADENITIS SUPPURATIVA
#23NOVEL ANTIBODY FORMAT
#24METHODS FOR THE TREATMENT OF OSTEOARTHRITIS
#25POLYPEPTIDES WITH ALTERED BINDING TO NEONATAL FC RECEPTOR (FCRN) AND METHODS OF USE
#26GOUT FLARE PREVENTION METHODS USING IL-1BETA BLOCKERS
#27ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE
#28LDL RECEPTOR-DIRECTED BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS
#29Methods of Using IL-1beta Compounds
#30DIAGNOSIS AND TREATMENT OF PRIMARY GRAFT DYSFUNCTION FOLLOWING LUNG TRANSPLANT
#31USE OF CANAKINUMAB
#32HUMAN ANTIBODY SPECIFIC FOR INTERLEUKIN-1ALPHA
#33TREATMENT OF HIDRADENITIS SUPPURATIVA
#34INTERLEUKIN-1 INHIBITION FOR COMBINATION TREATMENT OF PANCREATIC CANCER CACHEXIA
#35Treatment for neoplastic diseases
#36MEANS FOR REDUCING RADIO- AND CHEMOTHERAPY RESISTANCE AND ADVERSE EFFECTS
#37True human antibody specific for interleukin 1 alpha
#38True human antibody specific for interleukin 1 alpha
#39True human antibody specific for interleukin 1 alpha
#40True human antibody specific for interleukin 1 alpha
#41USE OF IL-1 BETA BINDING ANTIBODIES TO TREAT PERIPHERAL ARTERIAL DISEASE
#42USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITIS
#43TREATMENT OF HIDRADENITIS SUPPURATIVA
#44MATERIALS AND METHODS OF IL-1BETA BINDING PROTEINS
#45ANTIBODIES TO INTERLEUKIN-1BETA AND USES THEREOF
#46IL-1BETA BINDING ANTIBODIES FOR USE IN TREATING CANCER
#47Antibodies Against IL-1 Beta
#48TARGETED THERAPY FOR THE TREATMENT & PREVENTION OF LIFE-THREATENING COMPLICATIONS OF INFECTION
#49GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL1B AND/OR IL1A
#50Compositions and Methods for the Systemic Treatment of Arthritis
#51APPLICATION OF AGENT IN PREPARATION OF MEDICINE FOR TREATING/INHIBITING PSORIASIS
#52IL-1 Binding Proteins
#53USE OF IL-1BETA BINDING ANTIBODIES
#54AGENTS THAT INTERFERE WITH IL-1BETA RECEPTOR SIGNALLING
#55ANTI-IL-1-BETA ANTIBODIES
#56COMBINATION OF ANTI TIM-3 ANTIBODY MBG453 AND ANTI TGF-BETA ANTIBODY NIS793, WITH OR WITHOUT DECITABINE OR THE ANTI PD-1 ANTIBODY SPARTALIZUMAB, FOR TREATING MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME
#57COMPOSITIONS AND METHODS FOR DELIVERING THERAPEUTIC ANTIBODIES USING PLATELET-DERIVED MICROPARTICLES
#58ANTI-INTERLEUKIN 1 BETA ANTIBODIES FOR TREATMENT OF SICKLE CELL DISEASE
#59USE OF IL-1BETA BINDING ANTIBODIES
#60Arthritis treatment
#61ANTI-INFLAMMATORY THERAPY IN ARRHYTHMOGENIC CARDIOMYOPATHY (ACM)
#62Clonal Hematopoiesis and Risk of Chronic Liver Disease
#63USE OF IL-1ß BINDING ANTIBODIES FOR TREATING NEUROINFLAMMATORY DISORDERS
#64COMPOSITIONS AND METHODS FOR TREATING LUNG, COLORECTAL AND BREAST CANCER
#65ANTIBODY FORMULATION
#66ANTIBODY TO HUMAN IL-1 BETA
#67USE OF THE IL-1BETA BINDING ANTIBODY CANAKINUMAB FOR TREATING OR ALLEVIATING SYMPTOMS OF PULMONARY SARCOIDOSIS
#68Bispecific Antibodies for use in treatment of NLRC4-GOF inflammasomapathy
#69Monoclonal anti-IL-1RAcP antibodies
#70METHOD FOR THE EXPRESSION OF AN ANTIBODY-MULTIMER-FUSION
#71TREATMENT OF HIDRADENITIS SUPPURATIVA
#72SGLT-2 INHIBITORS OR IL-1R ANTAGONISTS FOR REDUCTION OF HYPOGLYCAEMIA AFTER BARIATRIC SURGERY
#73Antibody binding to human IL-1β, preparation method therefor and use thereof
#74TREATMENT OF PSYCHIATRIC CONDITIONS
#75USE OF IL-1BETA BINDING ANTIBODIES
#76Treatment of brain ischemia-reperfusion injury
#77Antibody that binds to VEGF and IL-1beta and methods of use
#78Cancer treatment by blocking host-induced IL-1 in combination with radiotherapy
#79USE OF IL-1BETA BINDING ANTIBODIES
#80Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated Diseases
#81TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF
#82Use of IL-1 beta Binding Antibodies
#83USE OF CANAKINUMAB
#84COMBINATION THERAPY FOR CARDIOVASCULAR DISEASES
#85USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE
#86USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITIS
#87USE OF IL-1BETA BINDING ANTIBODY CANAKINUMAB FOR TREATING OR ALLEVATING SYMPTOMS PULMONARY SARCOIDOSIS
#88COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE INNER EAR DISEASE
#89TREATMENT OF ATOPIC DERMATITIS
#90COMBINATION OF INTERLEUKIN-2 WITH AN INTERLEUKIN 1 INHIBITOR, CONJUGATES AND THERAPEUTIC USES THEREOF
#91OPHTHALMOLOGICAL IMPLANT, METHOD FOR PRODUCING AN OPHTHALMOLOGICAL IMPLANT, AND USE OF A LIGAND FOR PRODUCING AN OPHTHALMOLOGICAL IMPLANT
#92Interleukin-1 inhibition for combination treatment of pancreatic cancer cachexia
#93METHODS OF USING PHARMACOLOGIC INHIBITORS OF TYPE 2 CYTOKINE SIGNALING TO TREAT OR PREVENT PANCREATIC CANCER
#94USE OF IL-1 BETA BINDING ANTIBODIES TO TREAT PERIPHERAL ARTERIAL DISEASE
#95Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#96Methods for treating degenerative disc disease and chronic lower back pain
#97Anti-IL-1β antibody and pharmaceutical composition thereof and use of same
#98METHODS OF TREATING AUTO-INFLAMMATORY SYNDROMES USING IL-1BETA ANTIBODIES
#99TREATMENT OF HIDRADENITIS SUPPURATIVA
#100HUMAN ANTIBODY SPECIFIC FOR INTERLEUKIN-1ALPHA
#101NOVEL ANTIBODY FORMAT
#102IL-1β neutralizing human monoclonal antibodies
#103IL-1β neutralizing human monoclonal antibodies
#104Methods of Using IL-1beta Compounds
#105Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1
#106METHODS FOR THE TREATMENT OF GOUT
#107IL-1β neutralizing human monoclonal antibodies
#108CARDIOVASCULAR RELATED USES OF IL-1BETA ANTIBODIES AND BINDING FRAGMENTS THEREOF
#109BISPECIFIC ANTIBODIES TO TNF-ALPHA AND IL-1BETA AND USES THEREOF
#110Monoclonal anti-IL-1RAcp antibodies
#111Delivering biological drugs to tissues
#112COMBINATION THERAPY FOR CARDIOVASCULAR DISEASES
#113Stable Dual Variable Domain Immunoglobulin Protein Formulations
#114LIQUID IL-1 BETA ANTIBODY FORMULATION HAVING PH OF 5.5 TO 7.0
#115USE OF INHIBITORS OF IL-36 PROTEOLYTIC PROCESSING FOR THE TREATMENT AND/OR REDUCTION OF INFLAMMATION
#116BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF
#117USE OF IL-1BETA BINDING ANTIBODIES
#118Nucleic acids encoding antibodies against IL-1 beta
#119Compositions and methods for the systemic treatment of arthritis
#120Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies
#121TREATMENT OF HIDRADENITIS SUPPURATIVA
#122Antibody to human IL-1 beta
#123USE OF CANAKINUMAB
#124USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITIS
#125USE OF CANAKINUMAB
#126Antibody that binds to VEGF and IL-1beta and methods of use
#127USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE
#128CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE
#129Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
#130Biological Products
#131Interleukin-1 inhibition for combination treatment of pancreatic cancer
#132TREATMENT OF HIDRADENITIS SUPPURATIVA
#133IL-1 Binding Proteins
#134Cancer treatment by blocking host-induced IL-1 in combination with radiotherapy
#135Arthritis treatment
#136Compositions and Methods for Treating Autoimmune Inner Ear Disease
#137Recombinant antibody and uses thereof
#138Neuronal and Oligodendrocyte Survival Modulation
#139PNEUMOCOCCAL INHIBITORY FACTOR COMPOSITIONS AND METHODS OF USE THEREOF
#140NOVEL ANTIBODY FORMAT
#141Methods for treating degenerative disc disease and chronic lower back pain
#142TREATMENT OF CANCER WITH ANTI-IL-1 ALPHA ANTIBODIES
#143Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseases
#144Method of reducing tumor growth with IL-1beta neutralizing human monoclonal antibodies
#145Dual specificity antibody fusions
#146Treatment for neoplastic diseases
#147Monoclonal anti-IL-1RAcP antibodies
#148USE OF IL-1beta BINDING ANTIBODIES
#149Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
#150Methods of treating a crystal induced arthropathy using IL-1beta antibodies
#151Nucleic acid encoding antibody to human IL-1 beta
#152Treatment of psychiatric conditions
#153USE OF IL-1 BETA BINDING ANTIBODIES TO TREAT PERIPHERAL ARTERIAL DISEASE
#154USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE
#155ANTIBODIES AGAINST IL-1 BETA
#156Treatment of hidradenitis suppurativa
#157Methods of Using IL-1beta Compounds
#158Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#159Cardiovascular related uses of IL-1β antibodies and binding fragments thereof
#160Human antibody specific for interleukin-1 alpha
#161Dual specificity antibody fusions
#162HOMOGENEOUS ANTIBODY POPULATIONS
#163TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF
#164Cachexia treatment
#165Phage-displayed single-chain variable fragment library
#166METHODS FOR THE TREATMENT OF GOUT
#167Dual Variable Domain Immunoglobulin and Uses Thereof
#168Chimeric antigen and T cell receptors and methods of use
#169Compositions and methods for the systemic treatment of arthritis
#170Method for treatment of inflammatory skin disorders with inhibitors of IL-36 proteolytic processing
#171Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV event
#172METHODS FOR TREATING CANCER
#173Anti-IL-1beta antibodies
#174Bispecific antibodies and methods of use in ophthalmology
#175Methods of Using IL-1beta Compounds
#176Stable Dual Variable Domain Immunoglobulin Protein Formulations
#177TREATMENT OF LYSOSOMAL DISORDERS (IL-1 ANTAGONISTS)
#178HUMANIZED ANTIBODIES
#179SINGLE-CHAIN MULTIVALENT BINDING PROTEIN COMPOSITIONS AND METHODS
#180Treatment of diabetes
#181Method of treating auto-inflammatory syndromes with IL-1beta antibodies related to canakinumab
#182IL-1 BINDING PROTEINS
#183Method of inhibiting human IL-1 beta by administering an antibody to human IL-1 beta
#184Arthritis Treatment
#185Treatment of dermatological pathologies
#186DRUG DELIVERY SYSTEM
#187Use of IL-1 β binding antibodies for treating peripheral arterial disease
#188ANTIGEN BINDING POLYPEPTIDES
#189Dual specificity antibody fusions
#190CXCR4 UP- AND DOWN-REGULATION FOR TREATMENT OF DISEASES OR DISORDERS
#191METHOD OF TREATING A PATHOLOGICAL SYNDROME
#192STABLE SOLID UNITS AND METHODS OF MAKING THE SAME
#193MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) PROMOTER POLYMORPHISM IN INFLAMMATORY DISEASE
#194Antibodies against IL-1 beta
#195Antibody locker for the inactivation of protein drug
#196TREATMENT OF CANCER WITH ANTI-IL-1 ALPHA ANTIBODIES
#197IL-1 FAMILY VARIANTS
#198Enhanced anabolic cytokine production and delivery system
#199Compositions and methods for the systemic treatment of arthritis
#200Methods and arrays for use in the same
#201Human antibody specific for interleukin-1alpha
#202Methods of treating Kawasaki disease using IL-1beta antibodies
#203DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 and/or IL-17
#204Methods of using IL-1β compounds to treat familial mediterranean fever (FMF)
#205Antigen binding polypeptides
#206TREATMENT OF AUTOPHAGY-BASED DISORDERS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTIC AND SCREENING ASSAYS AND KITS
#207Antigen binding polypeptides
#208COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS
#209ANTI-INTERLEUKIN-1 (IL-1) ANTIBODY USED AS A TARGETING AGENT TO TREAT ARTHRITIS AND OTHER DISEASES
#210DUAL SPECIFICITY ANTIBODIES AND METHODS OF MAKING AND USING
#211Dual Variable Domain Immunoglobulin and Uses Thereof
#212Human antibody specific for IL-1alpha
#213Dual Variable Domain Immunoglobulin and Uses Thereof
#214Humanized antibodies
#215Method for use in the treatment of aneurysm
#216TREATMENT OF OSTEOARTHRITIS AND PAIN
#217IL-1β neutralizing human monoclonal antibodies
#218COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CANCER
#219NOVEL COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING CANCER METASTASIS
#220METHODS FOR TREATING ACNE
#221Dual Variable Domain Immunoglobulin and Uses Thereof
#222DUAL SPECIFICITY ANTIBODIES AND METHODS OF MAKING AND USING
#223METHODS FOR THE TREATMENT OF GOUT
#224Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV event
#225Dual specific binding proteins directed against IL-1β and/or IL-17
#226ANTI-IL-1BETA (INTERLEUKIN-1BETA) ANTIBODY-BASED PROPHYLACTIC THERAPY TO PREVENT COMPLICATIONS LEADING TO VASO-OCCLUSION IN SICKLE CELL DISEASE
#227IL-1 BINDING PROTEINS
#228IL-1 ALPHA DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
#229Human lubrication gel
#230Dual specific binding proteins directed against IL-1 and/or IL-17
#231Methods for the treatment of IL-1β related diseases
#232High-throughput system and method for identifying antibodies having specific antigen binding activities
#233Methods for the treatment of uveitis with IL-1β binding antibodies
#234Dual variable domain immunoglobulins and uses thereof
#235IL-1 binding proteins
#236DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
#237DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
#238IL-1 binding proteins
#239IL-1 binding proteins
#240IL-1 binding proteins
#241Method for the treatment of acne by administering IL-1β antibody
#242Dual specificity antibody fusions
#243Nucleic acids encoding a human monoclonal antibody that specifically binds to IL-1α
#244IL-1 binding proteins
#245STABLE DUAL VARIABLE DOMAIN IMMUNOGLOBULIN PROTEIN FORMULATIONS
#246DUAL SPECIFICITY ANTIBODIES AND METHODS OF MAKING AND USING
#247ANTI-IL1ALPHA/BETA DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF
#248Antibody to human IL-1 beta
#249Dual Variable Domain Immunoglobulin and Uses Thereof
#250IL-1 binding proteins
#251TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF
#252Treatment of diabetes
#253Method of treating hypertension disorder and a pharmaceutical agent
#254METHODS FOR IMPROVEMENT OF BETA CELL FUNCTION
#255Pharmaceutical compositions comprising IL-1B binding antibodies and fragments thereof
#256IL-1F8 polypeptides
#257Anti-IL-1β antibodies
#258Methods of treating vascular disease using an IL-1beta Antibody
#259IL-1 BINDING PROTEINS
#260IL-1 BINDING PROTEINS
#261TREATING DIABETES USING INHIBITORS OF IL-1
#262TREATMENT OF CACHEXIA BY TARGETING INTERLEUKIN-1 BETA
#263Human lubrication gel
#264Method for killing IL-1 alpha expressing cells
#265Inhibiting cell migration
#266DUAL-SPECIFIC IL-1A/ IL-1B ANTIBODIES
#267ANTIBODIES TO IL-1BETA AND IL-18, FOR TREATMENT OF DISEASE
#268HOMOGENEOUS ANTIBODY POPULATIONS
#269Anti-interleukin-1 (IL-1) antibody used as a targeting agent to treat arthritis and other diseases
#270Cachexia treatment
#271Treatment of inflammatory skin disease
#272Dual Variable Domain Immunoglobulin and Uses Thereof
#273Methods of treating gout using IL-1BETA antibodies
#274Disulfide Stabilised Multivalent Antibodies
#275Antibody formulation
#276Modulation of pathogenic CD14+/CD16+ monocytes
#277IL-1 Binding Proteins
#278COMPOSITIONS AND METHODS FOR THE SYSTEMIC TREATMENT OF ARTHRITIS
#279Treatment of Dermatological Pathologies
#280Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#281USE OF TNF-ALPHA INHIBITORS FOR TREATING A NERVE DISORDER MEDIATED BY NUCLEUS PULPOSUS
#282Treatment of osteoarthritis and pain
#283Dual variable domain immunnoglobulins and uses thereof
#284Interleukin-1 Alpha Antibodies and Methods of Use
#285Compositions and Methods for the Systemic Treatment of Arthritis
#286Use of TNF-alpha Inhibitors for Treating a Nerve Disorder Mediated by Nucleus Pulposus
#287Enhanced Binding of Pro-Inflammatory Cytokines by Polysaccharide-Antibody Conjugates
#288Antigen binding polypeptides
#289Treatment for neoplastic diseases
#290Use of IL-1beta compounds
#291Dual variable domain immunoglobulins and uses thereof
#292Interleukin-1 Alpha Antibodies and Methods of Use
#293IL-1F5 polypeptides
#294Interleukin-1 alpha antibodies and methods of use
#295Interleukin-1α antibodies and methods of use
#296Interleukin-1 alpha antibodies and methods of use
#297Method of treating inflammatory eye disease with IL-1β binding antibodies
#298Methods for the treatment of IL-1β related conditions
#299Methods for improvement of beta cell function with anti-IL-1β antibodies or fragments thereof
#300Methods for treating IL-1β related diseases by administering an anti-IL-1β antibody